Literature DB >> 19760692

Phosphatidylethanolamine-binding proteins, including RKIP, exhibit affinity for phosphodiesterase-5 inhibitors.

Poupak Dadvar1, Duangnapa Kovanich, Gert E Folkers, Klaus Rumpel, Reinout Raijmakers, Albert J R Heck.   

Abstract

Identifying protein "interactors" of drugs is of great importance to understand their mode of action and possible cross-reactivity to off-target protein binders. In this study, we profile proteins that bind to PF-3717842, a high-affinity phosphodiesterase-5 (PDE5) inhibitor, by using a refined affinity pulldown approach with PF-3717842 immobilized beads. By performing these pulldowns in rat testis tissue lysate, we strongly and specifically enriched for PDE5 and a few other PDEs. In addition to these expected affinity-enriched proteins we also detect rodent-specific phosphatidylethanolamine-binding protein 2 (PEBP2), as a putative binder to the PDE5 inhibitor. By using recombinant forms of the related murine mPEBP2, mPEBP1 and human hPEBP1 (also known as Raf kinase inhibitor protein or RKIP) we confirm that they all can bind strongly to immobilized as well as soluble PF-3717842. As the phosphatidylethanolamine-binding proteins are involved in various important signal transduction pathways, the synthetic PDE5 inhibitor used here might form a platform to synthesize enhanced binders/inhibitors of the family of PEBP proteins. Our approach shows how chemical proteomics might be used to profile the biochemical space (interactome) of small molecule inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19760692     DOI: 10.1002/cbic.200900452

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  4 in total

Review 1.  The role of targeted chemical proteomics in pharmacology.

Authors:  Chris W Sutton
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  Locostatin Disrupts Association of Raf Kinase Inhibitor Protein With Binding Proteins by Modifying a Conserved Histidine Residue in the Ligand-Binding Pocket.

Authors:  Anwar B Beshir; Christian E Argueta; Lochana C Menikarachchi; José A Gascón; Gabriel Fenteany
Journal:  For Immunopathol Dis Therap       Date:  2011

3.  Ligand binding study of human PEBP1/RKIP: interaction with nucleotides and Raf-1 peptides evidenced by NMR and mass spectrometry.

Authors:  Laurette Tavel; Lucie Jaquillard; Andreas I Karsisiotis; Fabienne Saab; Laurence Jouvensal; Alain Brans; Agnès F Delmas; Françoise Schoentgen; Martine Cadene; Christian Damblon
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

Review 4.  The proteomics big challenge for biomarkers and new drug-targets discovery.

Authors:  Rocco Savino; Sergio Paduano; Mariaimmacolata Preianò; Rosa Terracciano
Journal:  Int J Mol Sci       Date:  2012-10-29       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.